These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
843 related articles for article (PubMed ID: 20213096)
1. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096 [TBL] [Abstract][Full Text] [Related]
2. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833 [TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526 [TBL] [Abstract][Full Text] [Related]
4. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417 [TBL] [Abstract][Full Text] [Related]
5. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter. He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073 [TBL] [Abstract][Full Text] [Related]
6. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy]. Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft. Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258 [TBL] [Abstract][Full Text] [Related]
8. [Specific antitumor effect of adeno-associated virus vector carrying TRAIL gene under the control of hTERT promoter]. Qi R; Cai Y; Li BH; Lin ZX; Gu JF Ai Zheng; 2008 Oct; 27(10):1026-33. PubMed ID: 18851780 [TBL] [Abstract][Full Text] [Related]
9. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092 [TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase interference synergistically promotes tumor necrosis factor‑related apoptosis‑inducing ligand‑induced oral squamous cell carcinoma apoptosis and suppresses proliferation in vitro and in vivo. Zhao X; Zhang C; Le Z; Zeng S; Pan C; Shi J; Wang J; Zhao X Int J Mol Med; 2018 Sep; 42(3):1283-1294. PubMed ID: 29901096 [TBL] [Abstract][Full Text] [Related]
11. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Ma H; Liu Y; Liu S; Xu R; Zheng D Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690 [TBL] [Abstract][Full Text] [Related]
12. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790 [TBL] [Abstract][Full Text] [Related]
13. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
14. RNA interference-mediated hTERT inhibition enhances TRAIL-induced apoptosis in resistant hepatocellular carcinoma cells. Zhang RG; Zhao JJ; Yang LQ; Yang SM; Wang RQ; Chen WS; Peng GY; Fang DC Oncol Rep; 2010 Apr; 23(4):1013-9. PubMed ID: 20204286 [TBL] [Abstract][Full Text] [Related]
15. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
16. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894 [TBL] [Abstract][Full Text] [Related]
18. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement. Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904 [TBL] [Abstract][Full Text] [Related]
19. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of a novel adeno-associated virus vector targeting to telomerase activity in tumor cells. Wang YG; Wang JH; Zhang YH; Gu Q; Liu XY Acta Biochim Biophys Sin (Shanghai); 2004 Jul; 36(7):492-500. PubMed ID: 15248024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]